title: Clinical evaluation of a single dose of immune plasma for treatment of canine parvovirus infection.
abstract: OBJECTIVE
  To evaluate the efficacy of administration of a single 12-mL dose of canine parvovirus (CPV)-immune plasma for treatment of CPV enteritis.
  
  
  METHODS
  Prospective, randomized, double-blinded, placebo-controlled clinical trial.
  
  
  METHODS
  14 dogs with naturally occurring CPV enteritis.
  
  
  METHODS
  Dogs were assigned to treatment groups on the basis of randomization tables and were administered a single i.v. dose of CPV-immune plasma (treatment group) or an equivalent volume of saline (0.9% NaCl) solution (placebo group) within 18 hours after admission to the hospital. Treatment and outcome variables evaluated included neutrophil, monocyte, and CPV counts; number of days of hospitalization; changes in body weight; and cost of treatment.
  
  
  RESULTS
  When dogs treated with CPV-immune plasma were compared with dogs treated with saline solution, there were no significant differences detected among neutrophil or monocyte counts, magnitude of viremia, weight change, number of days of hospitalization, or cost of treatment.
  
  
  CONCLUSIONS
  Administration of a single 12-mL dose of immune plasma soon after the onset of CPV enteritis in dogs was not effective in ameliorating clinical signs, reducing viremia, or hastening hematologic recovery.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Ryan F
authors.initials: RF
authors.lastname: Bragg
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Duffy
authors.forename: Frank A
authors.initials: FA
authors.lastname: DeCecco
authors.forename: Donald K
authors.initials: DK
authors.lastname: Chung
authors.forename: Maura T
authors.initials: MT
authors.lastname: Green
authors.forename: Julia K
authors.initials: JK
authors.lastname: Veir
authors.forename: Steven W
authors.initials: SW
authors.lastname: Dow
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D004311:Double-Blind Method; D004751:Enteritis / Q000628:therapy / Q000662:veterinary* / Q000821:virology; D007106:Immune Sera / Q000276:immunology*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D010322:Parvoviridae Infections / Q000628:therapy / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000502:physiology*
chemical_list: D000914:Antibodies, Viral; D007106:Immune Sera; D007155:Immunologic Factors